Recombinant human interferon alfa-2b (Harbin Pharmaceutical Group Bioengineering)

重组人干扰素α2b软膏(假单胞菌)（哈药集团）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRecombinant human interferon alfa-2b (Harbin Pharmaceutical Group Bioengineering)
Drug Alias Name里亚美利分能
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokinesBiologics > Biosimilar
Mechanisms of ActionInterferon-alpha/beta receptor alpha chain stimulants
TargetsInterferon-alpha/beta receptor alpha chain
Therapy Area/IndicationsMultiple MyelomaLymphoma, Non-HodgkinLeukemia, Myelogenous, Chronic +[7] 
Global Approved IndicationsMultiple MyelomaLymphoma, Non-HodgkinLeukemia, Myelogenous, Chronic +[7] 
Approved Indications in ChinaMultiple MyelomaLymphoma, Non-HodgkinLeukemia, Myelogenous, Chronic +[7] 
Original Approved Country/TerritoryMainland China
Original Approved Date1996/01/01
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesHarbin Pharmaceutical Group Holding Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHarbin Pharmaceutical Group Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsMultiple MyelomaLymphoma, Non-HodgkinLeukemia, Myelogenous, Chronic +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeL03AB05
Related LinksN/A